Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.

Saved in:

Bibliographic Details
Title:	Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Authors:	Sordi V; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Monti P; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Lampasona V; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Melzi R; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Pellegrini S; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Keymeulen B; The Belgian Diabetes Registry, Academic Hospital and Diabetes Research Centre, Vrije Universiteit Brussel, Brussels, Belgium., Gillard P; Department of Endocrinology, University Hospitals Leuven-Katholieke Universiteit Leuven, Leuven, Belgium., Linn T; Clinical Research Unit, Medical Clinic and Polyclinic III, Center of Internal Medicine, Justus Liebig University, Giessen, Germany., Bosi E; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.; Università Vita-Salute San Raffaele, Milan, Italy., Rose L; Zentrum für Diabetes und Gefäßerkrankungen Münster, Munster, Germany., Pozzilli P; Department of Endocrinology and Metabolic Diseases, University Campus Bio-Medico, Rome, Italy., Giorgino F; Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy., Cossu E; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy., Piemonti L; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Source:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jun 20; Vol. 14, pp. 1175640. Date of Electronic Publication: 2023 Jun 20 (Print Publication: 2023).
Publication Type:	Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-2392
DOI:	10.3389/fendo.2023.1175640